Abstract
Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have